Skip to main content
logo
Novartis AG (VIE:NOVN)
Austria flag Austria · Delayed Price · Currency is EUR
130.70
+3.78 (2.98%)
At close: Feb 4, 2026

Revenue Breakdown

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013FY 2012
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16 Dec '15 Dec '14 Dec '13 Dec '12
Innovative Medicines Revenue
54.53B
Revenue (Other)
2.14B
Revenue (Total)
56.67B

Revenue by Geography

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013FY 2012
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16 Dec '15 Dec '14 Dec '13 Dec '12
United States Revenue (Post-Q2 2023 Reporting)
23.33B
Europe Revenue (Post-Q2 2023 Reporting)
16.73B
Asia/Africa/Australasia Revenue (Post-Q2 2023 Reporting)
10.80B
Canada and Latin America Revenue (Post-Q2 2023 Reporting)
3.68B
Revenue (Other)
2.14B
Revenue (Total)
56.67B

Revenue Breakdown 2

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013FY 2012
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16 Dec '15 Dec '14 Dec '13 Dec '12
Cardiovascular, Renal And Metabolic Revenue
8.96B
Immunology Revenue
10.29B
Neuroscience Revenue
5.99B
Oncology Revenue
16.83B
Established Brands Revenue
12.46B
Revenue (Total)
56.67B

Key Performance Indicators

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013FY 2012
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16 Dec '15 Dec '14 Dec '13 Dec '12
Cosentyx Revenue
6.67B
Entresto Revenue
7.75B
Tasigna Revenue
1.10B
Lucentis Revenue
643.00M
Updated Dec 31, 2025. Data Source: Fiscal.ai.